Skip header and navigation

1 records – page 1 of 1.

Assessing the appropriateness of combining economic data from multinational clinical trials.

https://arctichealth.org/en/permalink/ahliterature184987
Source
Stat Med. 2003 Jun 30;22(12):1955-76
Publication Type
Article
Date
Jun-30-2003
Author
John R Cook
Michael Drummond
Henry Glick
Joseph F Heyse
Author Affiliation
Health Economic Statistics, Merck Research Laboratories, UN-A102, West Point, PA 19486, U.S.A.
Source
Stat Med. 2003 Jun 30;22(12):1955-76
Date
Jun-30-2003
Language
English
Publication Type
Article
Keywords
Anticholesteremic Agents - therapeutic use
Data Interpretation, Statistical
Health Care Costs
Humans
Multicenter Studies as Topic - economics - methods
Randomized Controlled Trials as Topic - economics - methods
Scandinavia
Simvastatin - therapeutic use
Abstract
Because of the potential for large variability among countries in the utilization and cost of health care resources, it is important to assess the appropriateness of combining economic data across the countries in a multinational clinical economic trial. We show how available tests for interaction can be applied to economic endpoints, including cost-effectiveness ratios and net health benefits. This analysis includes a characterization of possible interactions being quantitative or qualitative in nature. In the absence of interaction, a pooled estimate of the economic endpoint should be representative of the participating countries. We explore the analytic issues by further analysing data from the Scandinavian Simvastatin Survival Study (4S).
PubMed ID
12802815 View in PubMed
Less detail